Nymox Pharmaceutical (NYMX)

Take Impact Assessment

Impact Scorecard
About

Overall impact

B (71)

Commentary

Nymox Pharmaceutical is a strong overall performer. With a 'B' rating of 71.3 for overall impact (84th percentile compared to all companies), Nymox Pharmaceutical ranks 10th out of 22 industry peers, behind Amag Pharmaceuticals, Fluoropharma Medical, Aspira Women’s Health and 6 others, and ahead of Palatin Technologies, Soleno Therapeutics, Quidel and 9 others. On top material causes for Nymox Pharmaceutical's industry (Pharmaceuticals & Biotech), Nymox Pharmaceutical performs well in Improved Mental Health (80.9 score), Access to Affordable Healthcare (95.9), Humane Treatment of Animals (81.0) and 3 other causes where it received an 'A' score and performs poorly in Accountable Institutions (37.8 score) and Reduced Green House Gas Emissions (21.3).

... read full commentary

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact

Cause			NYMX

Peer rank

Overall impact

Log in to view this information

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Nymox Pharmaceutical

Founded

1989

Employees

Sector

Health Care

Industry

Health Care Equipment & Supplies

Sub-industry

Health Care Equipment

SASB industry

Biotechnology & Pharmaceuticals

Headquarters

Quebec, Bahamas

Share classes

NYMX

More info

https://nymox.com

Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage, and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.

Material causes

Ethos considers the following causes material for Nymox Pharmaceutical, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

Access to affordable healthcare

Ensure universal access to affordable, quality healthcare

Accountable institutions

Build accountable and inclusive institutions at all levels

Child and maternal health

End preventable deaths of mothers and children, support reproductive health everywhere

Conflict-free mineral production

Reduce violence in the production of minerals

Decent, safe work opportunities

Promote full and productive employment for all, in safe work environments

Disaster readiness and effective aid

Be prepared for natural disasters and provide effective aid when disasters happen